How much does it cost to build a gabapentin (Neurontin) manufacturing plant?
No reliable, public “all-in” build cost figure for a gabapentin (Neurontin) manufacturing plant is provided in the information available here, and those costs typically vary widely based on the site location, capacity, cleanroom and containment needs, manufacturing process design (including solvent handling), utilities, and regulatory scope.
If you’re trying to estimate a range, the main cost drivers are usually:
- Plant scale (annual capacity in kg/yr)
- Process type and automation level (including API vs. finished dose manufacturing)
- Quality system requirements and data integrity infrastructure
- Containment and environmental controls (solvents, dust, waste treatment)
- Time to qualify equipment and validate processes
What does “plant cost” usually include for a drug (API/finished dose) site?
Most published or quoted capital figures for drug manufacturing projects (when they exist) bundle different scopes. “Manufacturing plant cost” can mean:
- Greenfield construction (new building plus equipment)
- Brownfield expansion (adding lines/equipment to an existing facility)
- API manufacturing capacity vs. finished-dose tablets/capsules capacity
- Validation/qualification and commissioning budgets
Without a specific project brief or capacity target, any single number would be guesswork.
Are there public cost figures tied to Neurontin/gabapentin sites?
For the specific question of “Gabapentin Neurontin manufacturing plant cost,” there does not appear to be a single widely cited public benchmark that can be used as a credible reference. Plant costs are often kept internal, and even when numbers are reported, they are usually tied to a particular contractor and project scope rather than “gabapentin in general.”
If you need a usable estimate, what details should you provide?
To estimate realistically, share:
- Country/state (or target region)
- Desired capacity (e.g., kg of API per year or number of finished-dose units per year)
- Whether you mean API (gabapentin bulk) or finished product (tablets/capsules)
- Target standard (commercial GMP vs. larger regulatory scope)
- Greenfield or using an existing pharma site
- Timeline goal (this can change cost due to overtime, procurement lead times, and scheduling)
With those inputs, a tighter cost range and a build-vs-expand approach can be outlined.
Related question: Why are manufacturing costs hard to compare across gabapentin facilities?
Even if two plants both say “gabapentin,” the cost can differ because of:
- Whether the site makes API, finishes dosage, or both
- Different impurity profiles and purification/solvent needs
- Site-specific permitting and environmental-control requirements
- Different GMP line designs and commissioning/validation effort
If you tell me what you mean by “plant” (API or finished dose) and the target capacity, I can translate that into a structured estimate and the typical budget categories you’d use.
Sources: none provided in the prompt.